Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Targeted therapies for RET-fusion cancer: Dilemmas and breakthrough.

Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie - 1 Dec 2020

Ding SiJie, Wang Rong, Peng ShunLi, Luo Xiaoqing, Zhong LongHui, Yang Hong, Ma YueYun, Chen ShiYu, Wang Wei

Abstract excerpt

Genomic profiling has revolutionized treatment options for patients with oncogene-driven cancers, such as epidermal growth factor receptor (EGFR) mutant carcinoma. Rearranged during transfection (RET) rearrangement, as one of the main activated oncogenes, has been well studied and found to be involved in the malignant behavior of carcinogenesis, resulting in acquired resistance to EGFR tyrosine kinase inhibitors...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Agents
Share to Drug Resistance, Neoplasm

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Gene Fusion

Share to Molecular Targeted Therapy

Share to Neoplasms

Share to Protein Kinase Inhibitors

Share to Proto-Oncogene Proteins c-ret

Share to Treatment Outcome

Source

Identifiers

PMID: 33125973
DOI: 10.1016/j.biopha.2020.110901

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Targeted therapies for RET-fusion cancer: Dilemmas and breakthrough.PMID 33125973Read ↗

Targeting RET-driven cancers: lessons from evolving preclinical and clinical landscapes.Semantic proximity Read ↗

Unraveling the Promise of RET Inhibitors in Precision Cancer Therapy by Targeting RET Mutations.Semantic proximity Read ↗

Hallmarks of RET and Co-occuring Genomic Alterations in RET-aberrant Cancers.Semantic proximity Read ↗

RET Inhibitors in RET Fusion-Positive Lung Cancers: Past, Present, and Future.Semantic proximity Read ↗

RET aberrant cancers and RET inhibitor therapies: Current state-of-the-art and future perspectivesSemantic proximity Read ↗

RET-oncogene-targeting drugs draw notice.Semantic proximity Read ↗

Advances in the Diagnosis and Treatment of a Driving Target: RET Rearrangements in non-Small-Cell Lung Cancer (NSCLC) Especially in China.Semantic proximity Read ↗

Progress and challenges in RET-targeted cancer therapy.Semantic proximity Read ↗

Therapeutic strategies in RET gene rearranged non-small cell lung cancerSemantic proximity Read ↗

RET Signaling Pathway in Human Cancer: Oncogenic Mechanisms, Selective Inhibitors, and Emerging Resistance Strategies.Semantic proximity Read ↗

Precision Targeted Therapy with BLU-667 for RET-Driven Cancers.Semantic proximity Read ↗

Targeting RET alterations in non-small cell lung cancer.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.